RxDoctor Payments Data

Ademuyiwa Adetunji, DPM

Primary Podiatric Medicine · Upper Marlboro, MDNPI 1487638854

Payments from drug & device makers

What this record shows

This record is dominated by other: $35,420 of the $38,568 with a category attached, or 91.8%. Convatec Inc. accounts for 91.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $35,478 and has fallen 99.6% since, to $131 in 2025.

$38,568in general payments, 2019–2025

Across 51 payments — averaging $756.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$35K
  • Triad Life Sciences Inc.$1K
  • Medimetriks Pharmaceuticals, Inc.$761
  • Organogenesis Inc.$397
  • Smith+Nephew$288
  • Paratek Pharmaceuticals, Inc.$157
  • plus $414 from 8 others

What the payments were for

  • Consulting fees$7002%
  • Travel & lodging$1,0083%
  • Food & beverage$1,4374%
  • Education$30%
  • Other$35,42092%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few primary podiatric medicine providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$308,692
Medicare patients
443
Services billed
2,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole13$13,955
Triamcinolone Acetonide40$885
Ciclopirox12$798
Ammonium Lactate22$466
Clindamycin Phosphate14$374
Allopurinol13$323
Terbinafine Hcl22$201
Pregabalin12$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$155$13,95513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few primary podiatric medicine providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other primary podiatric medicine in Upper Marlboro

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →